Back

State-of-the-art lecture in lipid lowering therapy and the atheroma .

26 August 2022 (16:30 - 16:50)
Organised by:
Congress Presentation Part of: Lipid-lowering therapy and the atheroma Pathophysiology and Mechanisms ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Stephen Nicholls

Monash University, Melbourne (Australia)

2 More presentations in this session

Presentation thumbnail
Longer-term safety of alirocumab with 24,610 patient-years of placebo-controlled observation: Further insights from the ODYSSEY OUTCOMES trial
Doctor S. Goodman (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
Interrelation between baseline plaque characteristics and changes in coronary atherosclerosis with the PCSK9-inhibitor alirocumab: Insights from the PACMAN-AMI randomized trial
Doctor K. Koskinas (Bern, CH)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid-lowering therapy and the atheroma
Video

The Event

Event poster

ESC Congress 2022

26 August 2022 16:30 CET
You may be interested in
thumbnail
Congress Presentation
Putting it all together: clinical implications of potent LDL lowering and plaque regression.
29 August 2022
thumbnail
Congress Presentation
Possible shifts in paradigms for lipid-lowering therapies in acute coronary syndrome patients: PCSK9 inhibitors from Day 1
2 September 2024
thumbnail
Congress Session
Transforming clinical practice: evaluating and managing LDL-C exposure for atherosclerotic cardiovascular disease (ASCVD) prevention
31 August 2025
thumbnail
Congress Presentation
Lipid-lowering therapies should be guided by vascular imaging rather than by plasma biomarkers: pro.
26 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources